Observational studyScience progress
The treatment outcome of radiation therapy for nasopharyngeal carcinoma in elderly patients: An observational, retrospective, single-center study.
Observational study in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThis study aimed to assess the treatment success and prognostic variables in elderly patients with nasopharyngeal carcinoma (NPC) who underwent definitive radiation therapy between January 2018 and December 2023.MethodsThe study employed a retrospective design and utilized the database system of our institution, which is centralized in a single location. A total of 125 patients, aged 60 or older, who were diagnosed with undifferentiated carcinoma of the nasopharynx (UCNT) based on histological confirmation, were included in the study. The data collection period spanned from January 2018 to December 2023.Results125 patients (93 male (74.4%), 32 females (25.6%); average age, 65.9 years) were identified, 16.8% were stage I, 34.4% stage II, 32% stage III, 16.8% stage IVA. The median follow-up for all 125 patients at the time of this analysis was 32.97 months (range 0.39-80.64 months). The mean OS was 64.75 ± 2.78 months. The 1-year and 5-year OS for the entire cohort were 93% and 69%, respectively. The mean disease-free survival (DFS) was 61.91 ± 2.87 months with a 5-year rate of 72%. According to multivariate analysis, overall survival was significantly influenced by both clinical stage (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.